BiotechTube

Dalteparin + Warfarin

Phase 2Completed
0 views this week 0 watching💤 Quiet
Interest: 35/100
35
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Embolism and Thrombosis

Conditions

Embolism and Thrombosis

Trial Timeline

Sep 1, 2002 → Mar 1, 2006

NCT ID
NCT00216866

About Dalteparin + Warfarin

Dalteparin + Warfarin is a phase 2 stage product being developed by Pfizer for Embolism and Thrombosis. The current trial status is completed. This product is registered under clinical trial identifier NCT00216866. Target conditions include Embolism and Thrombosis.

What happened to similar drugs?

11 of 20 similar drugs in Embolism and Thrombosis were approved

Approved (11) Terminated (3) Active (9)
✅MonteplaseEisaiApproved
✅Dalteparin (Fragmin) + Unfractionated heparinPfizerApproved
✅Dalteparin sodium + PlaceboPfizerApproved
✅Apixaban + Standard of CarePfizerApproved
✅ApixabanBristol Myers SquibbApproved
✅Alteplase + Unfractionated heparin + Placebo + ApixabanBristol Myers SquibbApproved
✅enoxaparin sodiumSanofiApproved

Hype Score Breakdown

Clinical
12
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT00216866Phase 2Completed

Competing Products

20 competing products in Embolism and Thrombosis

See all competitors
ProductCompanyStageHype Score
EdoxabanDaiichi SankyoPre-clinical
26
DU-176b 15mg + DU-176b 30mg + Enoxaparin sodium 20 mg (=2000IU)Daiichi SankyoPhase 2
35
Edoxaban + Dalteparin + Low molecular weight heparinDaiichi SankyoPhase 3
40
EdoxabanDaiichi SankyoPre-clinical
26
DS-1040b + Placebo + EnoxaparinDaiichi SankyoPhase 1/2
32
Edoxaban + Standard of CareDaiichi SankyoPhase 3
40
DU-176b + DU-176b + DU-176b + DU-176b + PlaceboDaiichi SankyoPhase 2
35
DS-9231 + PlaceboDaiichi SankyoPhase 2
27
15mg DU-176b + 30mg DU-176b + FondaparinuxDaiichi SankyoPhase 3
40
DU-176b (edoxaban) + Enoxaparin sodium 20mgDaiichi SankyoPhase 3
40
edoxaban + enoxaparin sodiumDaiichi SankyoPhase 3
40
edoxaban tosylate(DU-176b) + low molecular weight heparin/unfractionated heparin + warfarinDaiichi SankyoPhase 3
40
YM150Astellas PharmaPhase 3
40
YM150 + enoxaparinAstellas PharmaPhase 2
35
YM150Astellas PharmaPhase 3
40
YM150 + enoxaparinAstellas PharmaPhase 2/3
38
YM150 + Placebo + EnoxaparinAstellas PharmaPhase 2/3
38
YM150Astellas PharmaPhase 3
40
YM150Astellas PharmaPhase 2
35
YM150Astellas PharmaPhase 3
40